VMAT2 Inhibitor Use in Refractory Tourette's
Emerging, largely off-label positioning for a VMAT2 inhibitor in severe, treatment-refractory Tourette's — genuine uncertainty about where it fits once an earlier promising signal met a larger, null confirmatory trial.
"My glitch," is what E.M. calls his most disruptive tic, a sudden full-body jerk that has cost him two fainting-adjacent near-falls this year alone, and he says it with the flat, over-rehearsed delivery of someone who has had to explain it to a lot of people who weren't going to understand it anyway. He is 16, diagnosed with Tourette's disorder at 8, and has cycled through nearly every standard option this project's own case files would recognize: guanfacine, which helped modestly and stopped helping after a year; risperidone, discontinued after eighteen months for weight gain he found more distressing than the tics themselves; and aripiprazole, his most recent trial, which produced akathisia severe enough that he asked to stop after six weeks despite some real tic reduction. His tics remain severe by every standardized measure — frequent, physically forceful, and now carrying real injury risk.
His neurologist raised deutetrabenazine at the last visit, and E.M. has since read enough about it himself to arrive today with a specific, informed question rather than a vague hope: he found one open-label study describing a real reduction in tic severity, but also a larger trial's name attached to a very different-sounding result, and he wants to know honestly which one should matter more to a decision about his own body before he agrees to try a fourth medication.
What comes through most clearly in how E.M. talks about his own case isn't frustration exactly, though there's some of that too, but a kind of practiced clinical fluency most 16-year-olds never have reason to develop — he can list his own prior doses and discontinuation dates without checking his phone, and he's noticed, on his own, that each of his three prior trials failed for a genuinely different reason rather than the same one repeating: guanfacine simply stopped working, risperidone worked but cost him something he wasn't willing to keep paying, and aripiprazole's akathisia was its own distinct, intolerable problem unrelated to whether the drug was helping his tics at all. He wants whatever comes next evaluated with that same precision, not folded into a general sense that "medications haven't worked for him."
An honest look at a genuinely mixed evidence record
You found both studies, and you're right that they point in different directions. The earlier open-label phase 1b trial found a 37.6 percent reduction in tic severity on a blinded-rater scale after eight weeks — a real, statistically significant signal. But ARTISTS 2, the larger, properly randomized, placebo-controlled confirmatory trial in 158 children and adolescents, found no significant difference between deutetrabenazine and placebo at week eight, despite an early numeric trend in that direction during titration. The confirmatory trial is the one that should carry more weight — that's exactly the kind of gap between open-label promise and controlled result this drug class has now shown once.
I'd add a real caveat to that reading, not dispute it. ARTISTS 2's own placebo arm showed a substantial numeric improvement too — a well-documented feature of tic-severity trials generally, where expectation and natural fluctuation both move the needle regardless of active treatment. A null result against an unusually responsive placebo arm isn't quite the same claim as "the drug doesn't work for anyone," even though it's a completely fair reason not to expect it to work reliably as a general strategy.
That's a real distinction worth naming to him directly, but it doesn't change the practical recommendation — a drug that failed its confirmatory trial isn't a strong next step for a patient who has already had genuine trouble tolerating three prior agents, however real the placebo-response caveat is as a matter of trial methodology.
Given his actual situation — genuinely severe, injury-risk tics, and real trouble tolerating three separate mechanisms already — I don't think the confirmatory trial's null result should foreclose deutetrabenazine entirely, but it does argue against treating it as a confident next step. A time-limited trial, explicit outcome measures at eight weeks matching ARTISTS 2's own window, and a clear plan for what happens if it doesn't separate from his own baseline, treats this honestly as a reasonable option worth testing given how few remain, not as a drug we're confident will work.
Agreed: an eight-week deutetrabenazine trial with structured tic tracking against his own baseline, framed honestly to E.M. as a reasonable option given few remaining choices rather than an expected success.
E.M. said, near the end of the visit, that the honest framing — including being told plainly that the larger trial found no benefit on average — mattered more to him than being reassured it would probably work; he said he'd rather know the real odds than be managed.